Ocular Therapeutix to Showcase AXPAXLI Data at Clinical Trials Summit 2026
Event summary
- Ocular Therapeutix will present data on AXPAXLI (OTX-TKI) at Clinical Trials at the Summit 2026 on June 12-13, 2026.
- Key presentations include Phase 3 trial results for wet AMD and updates on the HELIOS program for nonproliferative diabetic retinopathy.
- Executive Chairman and CEO Pravin U. Dugel will participate in a fireside chat and panel discussion.
- AXPAXLI leverages Ocular’s ELUTYX proprietary bioresorbable hydrogel technology.
The big picture
Ocular Therapeutix’s participation in Clinical Trials at the Summit 2026 underscores the growing competition in retinal disease treatments, particularly for wet AMD and diabetic retinal diseases. The company’s focus on its ELUTYX technology positions it in a crowded market where differentiation through sustained drug delivery and efficacy will be critical. Success in these trials could accelerate its path to commercialization and expand its market share in ophthalmology.
What we're watching
- Clinical Efficacy
- Whether AXPAXLI’s Phase 3 trial results will demonstrate superior efficacy in wet AMD compared to existing treatments.
- Regulatory Pathway
- The pace at which Ocular Therapeutix can advance AXPAXLI through regulatory approvals for multiple retinal diseases.
- Pipeline Strategy
- How Ocular Therapeutix will leverage its ELUTYX technology across its pipeline, including next steps for OTX-TIC in glaucoma.